Founded in 2005 and headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC specializes in the engineering of novel biologics to treat anemias, cancers and their debilitating comorbidities by leveraging the multi-faceted core attributes of PEGylation technology. The company is led by Dr. Abraham Abuchowski, the inventor of PEGylation, the most successful drug delivery technology in history, now responsible for more than $30 billion in drug sales worldwide.  The company's lead product, SANGUINATE™, focuses on treating disorders caused by ischemia, hypoxia and/or hemolysis.  It is in clinical testing for the comorbidities of sickle cell disease and other anemia-related conditions with broader applications anticipated in the future.